Despoina Mparmparousi
Athens, ESYE31, Greece
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Visceral leishmaniasis and COVID-19 coinfection - A case report.
Journal: IDCases
Published: October 25, 2021
Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
Journal: Hematological oncology
Published: December 23, 2020
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.
Journal: Therapeutic advances in hematology
Published: July 08, 2020
Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: June 11, 2019
Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Journal: Journal of geriatric oncology
Published: March 28, 2019
The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry.
Journal: Cancer medicine
Published: September 08, 2018
The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Journal: Hematological oncology
Published: August 03, 2018
The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
Journal: American journal of hematology
Published: March 29, 2018
Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
Journal: American journal of hematology
Published: January 18, 2016
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.
Journal: British journal of haematology
Published: June 03, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026